Breaking News Instant updates and real-time market news.

TEVA

Teva

$18.55

0.95 (5.40%)

11:40
10/02/17
10/02
11:40
10/02/17
11:40

Teva calls outpace puts 6:1 as shares see strength

Teva calls outpace puts 6:1 as shares see strength. The stock up 95c to $18.55 on increasing volume of 11M shares on unconfirmed talk the FDA is considering ways to ease the path to market for complex generic drugs. More than 5K TEVA Oct 17.5 calls have changed hands. Oct 20, Oct 6th 19, and Oct 6th 19.5 calls are next most active. Total volume is 33K calls and 5.4K puts. 30-day implied volatility jumped 10% to 46.5.

TEVA Teva
$18.55

0.95 (5.40%)

09/18/17
RBCM
09/18/17
NO CHANGE
RBCM
Teva price target lowered to $15 from $21 at RBC Capital
RBC Capital analyst Randall Stanicky cut his price target on Teva as he believes that the new CEO will need time "to come up to speed," and the analyst is unsure what strategic options the new CEO can take that the board has not already considered. Stanicky says that the company's debt load "looks severe," while it faces multiple additional headwinds, including generic Copaxone and headwinds to its own generic business. He cut his price target on the shares to $15 from $21 and keeps an Underperform rating on the name.
09/19/17
CANT
09/19/17
NO CHANGE
Target $17
CANT
Neutral
Teva divestitures should remove covenant risk, says Cantor
Cantor Fitzgerald analyst Louise Chen says the valuation Teva Pharmaceutical received for its women's health franchise assets is higher than the Street expected. The sale should enable Teva to pay down sufficient debt to remain in compliance with its covenants at year end, Chen wrote yesterday in a research note. She believes the news should remove an overhang on the stock. The analyst keeps a Neutral rating on Teva with a $17 price target.
09/19/17
WELS
09/19/17
NO CHANGE
WELS
Market Perform
Assets sale a 'step in right direction' for Teva, says Wells Fargo
Wells Fargo analyst David Maris notes that Teva announced that it has entered into two separate agreements to sell the remaining assets in its specialty global women's health business for an aggregate of $1.38B. While the sale is a step in the right direction for Teva, the analyst notes that the proceeds amount to only small step toward lowering Teva's approximate $35B in debt. He reiterates a Market Perform rating on the shares.
09/21/17
BARD
09/21/17
NO CHANGE
Target $66
BARD
Baird physician survey positive for Neurocrine, shares rally
Baird analyst Brian Skorney says his firm's survey of 30 physicians is incrementally positive for Neurocrine Biosciences' (NBIX) Ingrezza. Tardive dyskinesia may be a much more active indication than originally expected, Skorney tells investors in a research note titled "Ingrezza Already a Big Hit Among Physicians." The analyst believes Ingrezza could be used three-times as often as Teva's (TEVA) Austedo. He sees reimbursement as a "minor hurdle" and thinks Ingrezza sales in Q3 could "blow expectations out of the water." Skorney raised his Q3 sales estimate for the drug to $12M from $8M, above the consensus of $10M. The analyst, while admitting he continues to expect the Ingrezza launch "to be rather slow and steady," keeps an Outperform rating on Neurocrine with a $66 price target. The stock in early trading is up $1.43 to $58.23.

TODAY'S FREE FLY STORIES

CRSP

Crispr Therapeutics

$59.61

-6.13 (-9.32%)

14:01
07/16/18
07/16
14:01
07/16/18
14:01
Periodicals
Crispr Therapeutics tells CNBC does not use methods described in paper »

Crispr Therapeutics told…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAS

Masco

$37.79

-0.22 (-0.58%)

14:00
07/16/18
07/16
14:00
07/16/18
14:00
Options
Bullish option play opened in Masco ahead of earnings »

Bullish option play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

CRSP

Crispr Therapeutics

$59.09

-6.65 (-10.12%)

13:55
07/16/18
07/16
13:55
07/16/18
13:55
Options
Crispr Therapeutics put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:50
07/16/18
07/16
13:50
07/16/18
13:50
General news
U.S. equities are up from earlier lows »

U.S. equities are up from…

ECA

Encana

$12.84

-0.4 (-3.02%)

13:45
07/16/18
07/16
13:45
07/16/18
13:45
Options
Encana call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

  • 09

    Oct

ADS

Alliance Data

$220.17

-23.32 (-9.58%)

13:44
07/16/18
07/16
13:44
07/16/18
13:44
Technical Analysis
Technical Take: Alliance Data comes off the lows of the day »

Shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 08

    Aug

CRM

Salesforce

$147.50

-0.18 (-0.12%)

13:39
07/16/18
07/16
13:39
07/16/18
13:39
Hot Stocks
Salesforce announces definitive agreement to acquire Datorama »

Salesforce has signed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 16

    Aug

YELP

Yelp

$40.33

0.54 (1.36%)

13:35
07/16/18
07/16
13:35
07/16/18
13:35
Options
Yelp put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LBIX

Leading Brands

$1.62

-0.06 (-3.57%)

13:32
07/16/18
07/16
13:32
07/16/18
13:32
Hot Stocks
Leading Brands announces resolution of temporary non-compliance with Nasdaq rule »

Leading Brands announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STM

STMicroelectronics

$22.84

0.2 (0.88%)

13:25
07/16/18
07/16
13:25
07/16/18
13:25
Options
STMicroelectronics call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

13:25
07/16/18
07/16
13:25
07/16/18
13:25
Conference/Events
Stephens agricultural analyst to hold an analyst/industry conference call »

Agriculture, Chemicals,…

EDIT

Editas Medicine

$36.20

-1.71 (-4.51%)

, NTLA

Intellia Therapeutics

$30.55

-2.05 (-6.29%)

13:23
07/16/18
07/16
13:23
07/16/18
13:23
Periodicals
Editas tells CNBC 'not specifically concerned about' Crisper study »

Editas Medicine (EDIT)…

EDIT

Editas Medicine

$36.20

-1.71 (-4.51%)

NTLA

Intellia Therapeutics

$30.55

-2.05 (-6.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVS

CVS Health

$68.30

-0.33 (-0.48%)

13:19
07/16/18
07/16
13:19
07/16/18
13:19
Periodicals
CVS apologizes after store managers call police on black customer, AP says »

CVS Health is apologizing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
07/16/18
07/16
13:17
07/16/18
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
07/16/18
07/16
13:16
07/16/18
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEGI

Pattern Energy

$17.84

0.75 (4.39%)

13:10
07/16/18
07/16
13:10
07/16/18
13:10
Options
Change of sentiment in Pattern Energy »

Change of sentiment in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:05
07/16/18
07/16
13:05
07/16/18
13:05
Conference/Events
The Brookings Institution to hold a conference »

7th Annual Municipal…

C

Citi

$69.22

2.22 (3.31%)

13:04
07/16/18
07/16
13:04
07/16/18
13:04
Hot Stocks
Citi reports June credit loss 2.60% vs. 2.78% last month »

Reports June 30-plus day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 14

    Jan

  • 15

    Apr

  • 13

    Jul

  • 15

    Oct

ORMP

Oramed

$5.89

-0.08 (-1.34%)

13:02
07/16/18
07/16
13:02
07/16/18
13:02
Downgrade
Oramed rating change  »

B. Riley FBR downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QDEL

Quidel

$69.21

0.03 (0.04%)

13:01
07/16/18
07/16
13:01
07/16/18
13:01
Hot Stocks
Quidel receives FDA clearance to market Solana Bordetella Complete Assay »

Quidel announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RRD

R.R. Donnelley

$5.53

-0.11 (-1.95%)

13:00
07/16/18
07/16
13:00
07/16/18
13:00
Options
4K RR Donnelley and Sons Aug 6 calls trade for 24c »

4K RR Donnelley and Sons…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:00
07/16/18
07/16
13:00
07/16/18
13:00
General news
Fed Chairman Powell's Monetary Policy testimony Tuesday won't break new ground »

Fed Chairman…

AMD

AMD

$16.85

0.575 (3.53%)

12:59
07/16/18
07/16
12:59
07/16/18
12:59
Hot Stocks
AMD jumps after analyst sees product transition to expand margins »

Shares of chip maker AMD…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORMP

Oramed

$5.89

-0.08 (-1.34%)

12:58
07/16/18
07/16
12:58
07/16/18
12:58
Downgrade
Oramed rating change  »

Oramed downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRC

California Resources

$39.03

-1.52 (-3.75%)

12:55
07/16/18
07/16
12:55
07/16/18
12:55
Options
California Resources put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.